BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Adamas Pharmaceuticals 

1900 Powell Street
Suite 1050
Emeryville  California  94608  U.S.A.
Phone: 510-450-3500 Fax: 510-428-0519


SEARCH JOBS




Industry
Pharmaceutical

Segment
Pharmaceuticals





 Company News
Adamas Pharmaceuticals (ADMS) Announces Closing Of Its Initial Public Offering 4/16/2014 8:50:54 AM    More...
Emeryville's Adamas Pharmaceuticals (ADMS) IPO Prices At $16, Low End Of Range 4/10/2014 7:03:52 AM    More...
Emeryville's Adamas Pharmaceuticals Files For $69 Million IPO 3/6/2014 7:29:56 AM    More...
Forest Laboratories, Inc. (FRX) And Adamas Pharmaceuticals Announce Forest’s Submission Of New Drug Application For Memantine Extended Release And Donepezil Fixed-Dose Combination For Alzheimer’s Disease 3/4/2014 10:05:48 AM    More...
Forest Laboratories, Inc. (FRX) Files Lawsuit Against Several Companies For Infringement Of NAMENDA XR ® Patents 2/3/2014 7:17:47 AM    More...
Adamas Pharmaceuticals Bags $40 Million From Forest Laboratories, Inc. (FRX) For Alzheimer's Drug NDA Filing 1/9/2014 7:11:00 AM    More...
Adamas Pharmaceuticals Presents Positive Clinical Data for ADS-5102, A Treatment for Levodopa-Induced Dyskinesia, at the World Parkinson's Congress 10/2/2013 10:02:31 AM    More...
Adamas Pharmaceuticals Presents Positive Phase 2/3 Results for ADS-5102 for the Treatment of Levodopa-Induced Dyskinesia (LID) in Parkinson's Disease 6/18/2013 10:04:04 AM    More...
Adamas Pharmaceuticals to Report Positive Phase 2/3 Results For ADS-5102 for the Treatment of Levodopa-Induced Dyskinesia in Parkinson's Disease 6/10/2013 10:28:41 AM    More...
Adamas Pharmaceuticals Announces Issuance of First U.S. Patent for Nurelin™ (Amantadine HCl Extended Release) Program 4/22/2013 11:12:57 AM    More...
123